Endra Life Sciences Inc Reports Results For The Quarter Ended In March: Earnings Summary

ENDRA Life Sciences

14/05/2024 22:41

* ENDRA Life Sciences Inc  NDRA.OQ  reported a quarterly
adjusted
loss of 26 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -93 cents.  The lone analyst forecast for the
quarter was for a loss of 27 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * ENDRA Life Sciences Inc's reported EPS for the quarter was
a
loss of 26 cents​.
    * The company reported a quarterly loss of $2.78 million.
    * ENDRA Life Sciences Inc shares had fallen by 49.8% this
quarter and lost 86.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 27% in
the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for ENDRA Life
Sciences Inc is $10.00 
This summary was machine generated from LSEG data May 14 at
09:40 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.27          -0.26          Beat
 Dec. 31 2023      -0.36          -0.05          Beat
 Sep. 30 2023      -0.43          -0.40          Beat
 Jun. 30 2023      -0.55          -0.43          Beat